Key result
Special Intervention reduced CVD mortality for highly adherent men but increased it for poorly adherent men compared to Usual Care.
Why the study?
Does Special Intervention reduce cardiovascular disease mortality in men compared to Usual Care, and how does adherence modify this effect?
RCT (n=12,338)
Randomized
Does Special Intervention reduce cardiovascular disease mortality in men compared to Usual Care, and how does adherence modify this effect?
The efficacy of a multiple risk factor intervention on CVD mortality is highly dependent on patient adherence, with benefits seen in highly adherent patients and potential harm in poorly adherent patients.
Answers are grounded in this paper and cite their sources.
Adherence modifies multiple risk factor intervention effects on CVD mortality; challenges uniform application and extends trials by identifying harm in poorly adherent men.
BACKGROUND: Patient adherence affects treatment efficacy, and surprisingly, adherence is frequently associated with reductions in mortality for those receiving placebo. METHODS: This study considers the role of trial adherence for men (N = 12,338) in the Multiple Risk Factor Intervention Trial (MRFIT), a prospective study of 9-year follow-up mortality following randomization to Special Intervention (SI) or Usual Care (UC). Annual visit attendance rates were used as a measure of adherence. RESULTS: A significant Adherence x Group Assignment interaction (p =.002) revealed that SI significantly reduced cardiovascular disease (CVD) mortality for highly adherent participants, RR =.91 (95% confidence interval [CI] =.84-.99) but significantly increased CVD mortality for poorly adherent participants, RR = 1.28 (95% CI = 1.05-1.57) when compared to UC. These associations remained after controlling for baseline characteristics (e.g., income), reported illness, or occurrence of a nonfatal CVD event during the trial. The beneficial effect of SI among the adherent participants was partly due to reduced smoking and diastolic blood pressure levels during the trial. CONCLUSIONS: SI significantly reduced the risk of CVD mortality for participants adherent with the MRFIT, and this effect was accounted for by positive changes in CVD risk factors. These findings suggest a method for evaluating treatment efficacy in subgroups determined by patient responses (e.g., adherence to annual assessment visits) to the treatment program after randomization.
No takes yet. Share an insight, caveat, or question.
Gump et al. (2003) conducted an RCT in Cardiovascular disease (n=12,338). Special Intervention (SI) vs. Usual Care (UC) was evaluated on Cardiovascular disease (CVD) mortality for highly adherent participants (RR 0.91, 95% CI 0.84-0.99, p=0.002 for interaction). Special Intervention reduced CVD mortality for highly adherent men but increased it for poorly adherent men compared to Usual Care.
Synapse has enriched 10 related papers. Consider them for comparative context: